Koca, SinanBesiroglu, MehmetOzcelik, MelikeKaraca, MustafaBilici, MehmetHacioglu, BekirDogu, Gamze G.2024-08-042024-08-0420211078-15521477-092Xhttps://doi.org/10.1177/1078155220924075https://hdl.handle.net/11616/99288Purpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. Materials and methods We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. Results The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade >= 3 toxicities were fatigue, anorexia, weight loss, and liver disorder. Conclusion Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.eninfo:eu-repo/semantics/closedAccessPazopanibsoft tissue sarcomatargeted therapyArticle2735415463241961810.1177/10781552209240752-s2.0-85084830817Q3WOS:000534051900001Q4